
Xencor (XNCR) Stock Forecast & Price Target
Xencor (XNCR) Analyst Ratings
Bulls say
Xencor is Overweight due to its XmAb technology platform, diversified pipeline with multiple potential catalysts, and strong cash position. The potential for positive data updates from Phase 1 expansion data on XmAb819 in ccRCC and updates on other pipeline candidates, combined with the company's focus on unmet medical needs in cancer and autoimmune diseases, contribute to a positive outlook. However, there are inherent clinical and competitive risks as well as the need for additional capital before commercialization of its portfolio.
Bears say
Xencor is facing a number of challenges with its pipeline, as its lead program XmAb819 has been deprioritized in favor of a combination approach with XmAb541 and XmAb808. The company's decision to open substudies in its Phase 1/2 protocol to test XmAb819 in earlier lines of therapy reflects concerns about the drug's effectiveness as a monotherapy, particularly in comparison to newer IO/IO and VEGF treatments. This strategy shift raises doubts about Xencor's ability to successfully commercialize its antibody therapeutics, and can lead to a decline in revenue from collaboration and licensing agreements.
This aggregate rating is based on analysts' research of Xencor and is not a guaranteed prediction by Public.com or investment advice.
Xencor (XNCR) Analyst Forecast & Price Prediction
Start investing in Xencor (XNCR)
Order type
Buy in
Order amount
Est. shares
0 shares